Elite in Scleroderma

Murray D. Baron

Montreal, QC, CA 
Elite in Scleroderma
Montreal, QC, CA 
OverviewLocationsClinical Research

Overview

Murray Baron practices in Montreal, Canada. Mr. Baron is rated as an Elite expert by MediFind in the treatment of Scleroderma. His top areas of expertise are Systemic Sclerosis (SSc), Scleroderma, Localized Scleroderma, and Acute Interstitial Pneumonia.

His clinical research consists of co-authoring 232 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 187 articles and participated in 2 clinical trials in the study of Scleroderma.

Gender
Male

Locations

Montreal, QC, Canada
Other Locations
Montreal, Canada
Quebec, QC, Canada
Prince Albert, SK, Canada
Hamilton, ON, Canada
Edmonton, AB, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

An International, Multicentre, Double-blind, Randomised Study of the Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis Patients as Assessed by Magnetic Resonance Imaging
An International, Multicentre, Double-blind, Randomised Study of the Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis Patients as Assessed by Magnetic Resonance Imaging
Enrollment Status: Completed
Publish Date: December 01, 2023
Intervention Type: Drug
Study Drugs: Diacerein, Celecoxib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: March 29, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
Enrollment Status: Completed
Publish Date: February 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

220 Total Publications

Severe fatigue is associated with diminished lung function and elevated Galectin-9 levels in early systemic sclerosis.
Severe fatigue is associated with diminished lung function and elevated Galectin-9 levels in early systemic sclerosis.
Journal: Frontiers in immunology
Published: June 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Baron's expertise for a condition
ConditionClose
View All 20 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile